PUMA BIOTECHNOLOGY, INC.

(CUSIP Number)

Form SC 13G March 18, 2019
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No.)*
(Amendment No. )*  Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.
Puma Biotechnology, Inc.  (Name of Issuer)
Puma Biotechnology, Inc.  (Name of Issuer)  Common stock, par value \$0.0001 per share

March 6, 2019
Date of Event Which Requires Filing of the Statement
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
"Rule 13d-1(b) xRule 13d-1(c) "Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act

but shall be subject to all other provisions of the Act (however, see the Notes).

```
CUSIP No. 74587V107 13G Page 2 of 12 Pages
```

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1.
 Partner Fund Management, L.P.
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2.(a)
 (b)
      X
 SEC USE ONLY
3.
 CITIZENSHIP OR PLACE OF ORGANIZATION
4.
 Delaware
               SOLE VOTING POWER
             5.
NUMBER OF
SHARES
               SHARED VOTING POWER
BENEFICIALLY
OWNED BY
               2,602,463 shares
EACH
```

7. SOLE DISPOSITIVE POWER

REPORTING

**PERSON** 

WITH 0

#### 8. SHARED DISPOSITIVE POWER

See Row 6 above

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9.

See Row 6 above

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

10. CERTAIN SHARES

..

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.

 $6.8\%^{1}_{-}$ 

\_

TYPE OF REPORTING PERSON

12.

IA; PN

The percentages reported in this Schedule 13G are based upon 38,497,981 shares of common stock outstanding as of <sup>1</sup> February 15, 2019 according Form 10-K filed by the issuer with the Securities and Exchange Commission on <sup>1</sup> March 1, 2019. All of the other numbers and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing.

#### CUSIP No. 74587V107 13G Page 3 of 12 Pages

```
NAME OF REPORTING PERSON
```

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

#### Partner Fund Management GP, LLC

#### CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.(a)

(b) x

SEC USE ONLY

3.

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

**Delaware** 

**SOLE VOTING POWER** 

5.

NUMBER OF 0

**SHARES** 

SHARED VOTING POWER

**BENEFICIALLY** 

OWNED BY 6

2,602,463 shares

**EACH** 

REPORTING

PERSON 7. SOLE DISPOSITIVE POWER

TYPE OF REPORTING PERSON

12.

00

#### CUSIP No. 74587V107 13G Page 4 of 12 Pages

```
NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
```

1.

#### Partner Investment Management, L.P.

#### CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

- 2.(a)
  - (b) x

SEC USE ONLY

3.

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

**Delaware** 

**SOLE VOTING POWER** 

5.

NUMBER OF 0

**SHARES** 

SHARED VOTING POWER

**BENEFICIALLY** 

OWNED BY 6

27,493 shares

**EACH** 

REPORTING

PERSON 7. SOLE DISPOSITIVE POWER

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11. **0.1%** 

-

TYPE OF REPORTING PERSON

12.

IA; PN

#### CUSIP No. 74587V107 13G Page 5 of 12 Pages

```
NAME OF REPORTING PERSON
```

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.

#### Partner Investment Management GP, LLC

#### CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.(a)

(b) x

SEC USE ONLY

3.

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

**Delaware** 

SOLE VOTING POWER

5.

NUMBER OF 0

**SHARES** 

SHARED VOTING POWER

**BENEFICIALLY** 

OWNED BY 6

27,493 shares

**EACH** 

REPORTING

PERSON 7. SOLE DISPOSITIVE POWER

TYPE OF REPORTING PERSON

12.

00

#### CUSIP No. 74587V107 13G Page 6 of 12 Pages

```
NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1.
```

#### Brian D. Grossman

#### CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

2.(a)

(b) x

SEC USE ONLY

3.

CITIZENSHIP OR PLACE OF ORGANIZATION

4.

U.S. Citizen

**SOLE VOTING POWER** 

5.

NUMBER OF 0

**SHARES** 

SHARED VOTING POWER

**BENEFICIALLY** 

OWNED BY 6

2,629,956 shares

**EACH** 

REPORTING

PERSON 7. SOLE DISPOSITIVE POWER

TYPE OF REPORTING PERSON

12. **IN** 

Edgar Filing: PUMA BIOTECHNOLOGY, INC. - Form SC 13G

```
CUSIP No. 74587V107 13G Page 7 of 12 Pages
```

```
NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
1.
 Christopher M. James
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2.(a)
 (b)
      X
 SEC USE ONLY
3.
 CITIZENSHIP OR PLACE OF ORGANIZATION
4.
 U.S. Citizen
               SOLE VOTING POWER
             5.
NUMBER OF
SHARES
               SHARED VOTING POWER
BENEFICIALLY
OWNED BY
               2,629,956 shares
EACH
REPORTING
```

7. SOLE DISPOSITIVE POWER

**PERSON** 

TYPE OF REPORTING PERSON

12. **IN** 

Edgar Filing: PUMA BIOTECHNOLOGY, INC. - Form SC 13G

CUSIP No. 74587V107 **13G** Page 8 of 12 Pages

Item 1(a)

Name of Issuer

Puma Biotechnology, Inc.

# Item 1(b) Address of Issuer's Principal Executive Offices 10880 Wilshire Boulevard, Suite 2150, Los Angeles, California 90024

#### Name of Person Filing

GP, LLC ("PFM-GP"), Partner Investment Management, L.P. ("PIM"), Partner Investment Management GP, LLC ("PIM-GP"), Brian D. Grossman ("Grossman") and Christopher M. James ("James" and, collectively with PFM, PFM-GP, PIM, PIM-GP and Grossman, the "Reporting Persons") with respect to shares of common stock of the above-named issuer owned by PFM Healthcare Emerging Growth Master Fund, L.P., a Cayman Islands limited Item partnership ("HEGM"), PFM Global Long Alpha Master Fund, L.P., a Cayman Islands limited partnership 2(a) ("GLAM"), PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("HCM"), PFM Healthcare Long Master Fund, L.P., a Cayman Islands limited partnership ("HCLM"), PFM Thematic Growth Master Fund, L.P., a Cayman Islands limited partnership ("TGM"), PFM Thematic Growth Institutional Master Fund, L.P., a Cayman Islands limited partnership ("TGIM"), PFM Therapeutics Master Fund, L.P., a Cayman Islands limited partnership ("TM"), PFM Healthcare Principals Fund, L.P., a Delaware limited partnership ("HCP"), and PFM Thematic Growth Principals Fund, L.P., a Delaware limited partnership ("TGP" and, collectively with HEGM, GLAM, HCM, HCLM, TGM, TGIM, TM and HCP, the "Funds").

This Schedule 13G is being jointly filed by Partner Fund Management, L.P. ("PFM"), Partner Fund Management

PFM is the investment advisor for each of the Funds other than HCP and TGP. PIM is the investment advisor for HCP and TGP. PFM-GP and PIM-GP are, respectively, the general partners of PFM and PIM. Grossman is the portfolio manager for the health care strategy for the Funds. James is the portfolio manager for the thematic strategy for the Funds. Grossman and James are co-managing members of PFM-GP and PIM-GP.

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

#### **Address of Principal Business Office**

Item The address of the principal business office of each of the Reporting Persons is c/o Partner Fund Management, **2(b)** L.P., 4 Embarcadero Center, Suite 3500, San Francisco, CA 94111.

#### Item Citizenship

Each of PFM and PIM is organized as a limited partnership under the laws of the State of Delaware. Each of

PFM-GP and PIM-GP is organized as a limited liability company under the laws of the State of Delaware. Each of Grossman and James is a U.S. citizen.

Item 2(d) Title of Class of Securities
Common stock, \$0.0001 par value

CUSIP No. 74587V107 13G Page 9 of 12 Pages

### Item 2(e) CUSIP Number 74587V107

# Item $3\frac{1}{a}$ If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is

- (a) "Broker or dealer registered under Section 15 of the Exchange Act;
- (b) "Bank as defined in Section 3(a)(6) of the Exchange Act;
- (c) "Insurance company as defined in Section 3(a)(19) of the Exchange Act;
- (d) "Investment company registered under Section 8 of the Investment Company Act;
- (e) "An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) "An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g)" A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) "A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) "A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) "Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

\_\_\_\_.

(i)

#### **Item 4 Ownership**

<b>r</b>		
A. Partner Fund Management, L.P. and Partner Fund Management GP, LLC		
(a) PFM ar	ad PFM-GP may be deemed to beneficially own 2,602,463 shares of Common Stock.	
(b) The number of share the Common Stock of	s PFM and PFM-GP may be deemed to beneficially own constitutes approximately 6.8% of utstanding.	
(c)Number of shares as	to which such person has:	
	(i) sole power to vote or to direct the vote: 0	
(ii)	shared power to vote or to direct the vote: 2,602,463	
(iii)	sole power to dispose or to direct the disposition of: 0	
(iv)	shared power to dispose or to direct the disposition of: 2,602,463	
B. Pa	rtner Investment Management, L.P. and Partner Investment Management GP, LLC	
(a) PIM	and PIM-GP may be deemed to beneficially own 27,493 shares of Common Stock.	
(b) The number of shares PIM and PIM-GP may be deemed to beneficially own constitutes approximately 0.1% of the Common Stock outstanding.		
(c) Number of shares as to which such person has:		

sole power to vote or to direct the vote: 0

# Edgar Filing: PUMA BIOTECHNOLOGY, INC. - Form SC 13G (ii) shared power to vote or to direct the vote: 27,493 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 27,493 C. Brian D. Grossman (a) Grossman may be deemed to beneficially own 2,629,956 shares of Common Stock. (b) The number of shares Grossman may be deemed to beneficially own constitutes approximately 6.8% of the Common Stock outstanding.

sole power to vote or to direct the vote: 0

shared power to vote or to direct the vote: 2,629,956

(i)

(ii)

- (iii) sole power to dispose or to direct the disposition of: 0
- (iv) shared power to dispose or to direct the disposition of: 2,629,956

#### D. Christopher M. James

- (a) James may be deemed to beneficially own 2,629,956 shares of Common Stock.
- The number of shares James may be deemed to beneficially own constitutes approximately 6.8% of the Common Stock outstanding.
- (c) Number of shares as to which such person has:
  - (i) sole power to vote or to direct the vote: 0
  - (ii) shared power to vote or to direct the vote: 2,629,956
  - (iii) sole power to dispose or to direct the disposition of: 0
  - (iv) shared power to dispose or to direct the disposition of: 2,629,956

#### Ownership of Five Percent or Less of a Class

Item

5

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ".

Item 6 Ownership of More than Five Percent on Behalf of Another Person Not Applicable

Item Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the
 Parent Holding Company

See Item 2 above

Item 8

**Identification and Classification of Members of the Group** 

Not Applicable

Item 9

**Notice of Dissolution of Group** 

Not Applicable

#### Certification

Item 10

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 74587V107 **13G** Page 12 of 12 Pages

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated this 18th day of March, 2019.

#### PARTNER FUND MANAGEMENT, L.P.

## PARTNER FUND MANAGEMENT GP, LLC

By: Partner Fund Management GP, LLC

its general partner

By:/s/ Darin Sadow

Darin Sadow, Authorized Signatory

By: /s/ Darin Sadow

Darin Sadow, Authorized Signatory

# PARTNER INVESTMENT MANAGEMENT, L.P.

# PARTNER INVESTMENT MANAGEMENT GP, LLC

By: Partner Investment Management GP, LLC, By:/s/ Darin Sadow

its general partner Darin Sadow, Authorized Signatory

By:/s/ Darin Sadow

Darin Sadow, Authorized Signatory

#### BRIAN D. GROSSMAN

#### **CHRISTOPHER M. JAMES**

By:/s/ Darin Sadow

By:/s/ Darin Sadow

Darin Sadow, attorney-in-fact\*

Darin Sadow, attorney-in-fact\*\*

Darin Sadow is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated \*August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.

Darin Sadow is signing on behalf of Christopher M. James as attorney-in-fact pursuant to a power of attorney dated \*\*August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.